a day ago
Nomura Sticks to Its Buy Rating for Dr. Reddy's Laboratories Ltd. (DRREDDY)
In a report released on July 25, Saion Mukherjee from Nomura maintained a Buy rating on Dr. Reddy's Laboratories Ltd., with a price target of INR1,660.00. The company's shares closed last Friday at INR1,277.90.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mukherjee covers the Healthcare sector, focusing on stocks such as Alkem Laboratories Ltd., Cipla Ltd, and Dr. Reddy's Laboratories Ltd.. According to TipRanks, Mukherjee has an average return of 15.0% and a 75.00% success rate on recommended stocks.
Currently, the analyst consensus on Dr. Reddy's Laboratories Ltd. is a Hold with an average price target of INR1,236.44, representing a -3.24% downside. In a report released on July 25, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a INR1,416.00 price target.
Based on Dr. Reddy's Laboratories Ltd.'s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of INR85.06 billion and a net profit of INR15.94 billion. In comparison, last year the company earned a revenue of INR70.83 billion and had a net profit of INR13.07 billion
